Loading...
NPI 1932139136 · Reno, NV · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Tejvir Singh is a hematology & oncology physician provider located in Reno, Nevada. This profile covers 61 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Tejvir Singh |
| Address | 5423 Reno Corporate Dr. |
| City | Reno |
| State | NV |
| ZIP | 89511 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | July 3, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.5M |
| Medicaid | $280 |
This profile shows a cancer-focused outpatient practice centered on high-cost oncology biologics: the top three Medicare drugs are J9271, J9299, and J9144, and the precomputed top-3 Medicare codes account for 68.3% of this provider's total Medicare revenue. Those codes include J9271 (pembrolizumab) with $782.6K revenue (31.9% of Medicare revenue), J9299 (nivolumab) with $491.5K (20.0%), and J9144 (daratumumab) with $403.6K (16.4%), which together indicate a drug‑heavy oncology infusion practice rather than primarily procedural or surgical services.
Revenue concentration is acute on Medicare and effectively absent on Medicaid: total Medicare revenue is $2.5M while total Medicaid revenue is $276, so Medicare dominates this provider's public-payer mix. On Medicaid the precomputed top-3 codes account for 100.0% of Medicaid revenue and the only Medicaid code reported is 85025 (CBC) with $266 revenue, showing Medicaid billing is minimal and limited to basic lab services.
Service-line operations are consistent with in-office infusion and medical oncology E/M care: chemotherapy administration and infusion codes such as 96413 ($49.6K, 2.0% of Medicare revenue), 96417 ($7.5K, 0.3%), and G0498 ($8K, 0.3%) appear alongside high-revenue biologic drug codes, supporting a model that combines drug infusion with outpatient follow-up. The presence of sustained infusion and add‑on codes (96415, 96417) suggests multi-drug infusion sessions and continued infusion management are part of the practice workflow.
Competitive standing by national ranks is mixed: for leading immunotherapy drugs the provider is a typical to modest participant—J9271 ranks #493 of 1841 providers (73rd percentile) and J9299 ranks #157 of 505 (69th percentile)—indicating unremarkable volumes relative to national peers for those high-revenue medicines. In contrast, certain utilization and visit codes are extreme outliers: 99214 ranks in the 99th percentile and 99215 in the 98th percentile, reflecting unusually high billed E/M visit volume compared with national peers.
There are notable statistical outliers among specific codes despite generally typical oncology drug volumes: J0894 (decitabine) is labeled an "extreme outlier" and ranks #1 of 37 providers nationally (100th percentile) even though its absolute revenue is $9.5K (0.4% of Medicare revenue), and J0897 (denosumab) is "notably above typical" at the 95th percentile with $289.4K revenue (11.8% of Medicare revenue). These outlier labels suggest idiosyncratic prescribing or case-mix for particular agents that differ from broader oncology peers.
The profile signals a high reliance on Medicare reimbursement streams for specialty oncology drugs: the top Medicare drug alone, J9271, accounts for $782.6K (31.9% of Medicare revenue) and the precomputed note that top three Medicare codes drive 68.3% of Medicare revenue underscores concentration risk if drug mix or reimbursement changes. By contrast, Medicaid contributes essentially no specialty drug revenue and appears limited to routine lab billing (85025 with $266, 100.0% of Medicaid revenue).
Tenure and stability: the provider's NPI was enumerated on 2006-07-03 (approximately 20 years ago), indicating long-standing enrollment that aligns with established clinical operations and the accumulation of the reported Medicare billing profile. That longevity, combined with high E/M percentiles, suggests a sustained patient panel and ongoing outpatient oncology practice presence.
State-level presence on Medicaid is minimal despite active Medicare participation: the Medicaid CBC code 85025 has $266 revenue and ranks #137 of 157 in-state (13th percentile), indicating below-average Medicaid utilization versus Nevada peers. This contrast—strong Medicare oncology billing versus negligible Medicaid activity—should be considered when assessing network access, reimbursement risk, and contract negotiations with state plans.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
61 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 18,200 | $40 | $782.6K |
| J9299 | Injection, nivolumab, 1 mg | 20,480 | $20 | $491.5K |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 10,620 | $40 | $403.6K |
| J0897 | Injection, denosumab, 1 mg | 16,080 | $20 | $289.4K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,640 | $100 | $161K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 600 | $100 | $62.4K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 430 | $140 | $61.1K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 480 | $100 | $49.6K |
| J9041 | Injection, bortezomib, 0.1 mg | 3,960 | $1 | $15.8K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | 110 | $140 | $14.7K |
Showing 1–10 of 61
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 61 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
61 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 10 | 40 | 13,000 | $40 | $625.8K |
| J9144 | 4 | 10 | 9,180 | $40 | $445.4K |
| J9299 | 3 | 10 | 14,400 | $20 | $362K |
| J0897 | 4 | 70 | 3,630 | $20 | $94.6K |
| Q5111 | 4 | 10 | 400 | $110 | $46.4K |
| 99233 | 823 | 1,150 | 150 | $90 | $26.8K |
| J9217 | 25 | 40 | 120 | $130 | $23.9K |
| 96413 | 7 | 70 | 210 | $100 | $23.7K |
| 99232 | 975 | 1,340 | 140 | $60 | $23.7K |
| 84443 | 43 | 80 | 50 | $20 | $22.7K |
Showing 1–10 of 61
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 40 | $10 | $270 |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 137 | 160 | 1,190 | $1 | $39.8K |
Other providers in the same ZIP code as Tejvir Singh, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.